Fungicidal activity of lysozyme is inhibited in vitro by commercial sinus irrigation solutions

American Journal of Rhinology and Allergy

Volumn 26, Issue 4, 2012, Pages 298-301

  Woods, Charmaine M ^a   Hooper, David N ^a   Ooi, Eng H ^a,b   Tan, Lor Wai ^b   Carney, A Simon ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOZYME;

ARTICLE; ASPERGILLUS FUMIGATUS; CHRONIC RHINOSINUSITIS; COLONY FORMING UNIT; CONTROLLED STUDY; FUNGICIDAL ACTIVITY; IN VITRO STUDY; IONIC STRENGTH; NASAL LAVAGE; NONHUMAN;

ANTIFUNGAL AGENTS; CHRONIC DISEASE; HUMANS; IMMUNITY, INNATE; MURAMIDASE; OSMOLAR CONCENTRATION; PARANASAL SINUSES; RHINITIS; SINUSITIS; SOLUTIONS; THERAPEUTIC IRRIGATION;

EID: 84864145073     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2012.26.3793     Document Type: Article

References (39)

1. Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: Definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg 129(suppl 3):S1-S32, 2003.
2. Australian Institute of Health and Welfare. Asthma, chronic obstructive pulmonary disease and other respiratory diseases in Australia. Asthma series. Cat. no. ACM 20. Canberra: AIHW, 2010.
3. Anand VK. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl 193:3-5, 2004. (Pubitemid 38623547)
4. Tan BK, Schleimer RP, and Kern RC. Perspectives on the etiology of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 18:21-26, 2010.
5. Timperley D, Schlosser RJ, and Harvey RJ. Chronic rhinosinusitis: An education and treatment model. Otolaryngol Head Neck Surg 143(suppl 3):S3-S8, 2010.
6. Hsu J, and Peters AT. Pathophysiology of chronic rhinosinusitis with nasal polyp. Am J Rhinol Allergy 25:285-290, 2011.
7. Reh DD, Wang Y, Ramanathan M Jr, and Lane AP. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 24:105-109, 2010.
8. Guilemany JM, Alobid I, and Mullol J. Controversies in the treatment of chronic rhinosinusitis. Expert Rev Respir Med 4:463-477, 2010.
9. Ramanathan M Jr, and Lane AP. Innate immunity of the sinonasal cavity and its role in chronic rhinosinusitis. Otolaryngol Head Neck Surg 136:348-356, 2007. (Pubitemid 46282189)
10. Ooi EH, Psaltis AJ, Witterick IJ, and Wormald PJ. Innate immunity. Otolaryngol Clin North Am 43:473-487, vii, 2010.
11. Ooi EH, Wormald P-J, and Tan LW. Innate immunity in the paranasal sinuses: A review of nasal host defenses. Am J Rhinol 22:13-19, 2008. (Pubitemid 351310946)
12. Do TQ, Moshkani S, Castillo P, et al. Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid. J Immunol 181:4177-4187, 2008.
13. Lee JT, Jansen M, Yilma AN, et al. Antimicrobial lipids: novel innate defense molecules are elevated in sinus secretions of patients with chronic rhinosinusitis. Am J Rhinol Allergy 24:99-104, 2010.
14. Cole AM, Liao HI, Stuchlik O, et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 169:6985-6991, 2002. (Pubitemid 36899286)
15. Kirby AJ. The lysozyme mechanism sorted - After 50 years. Nat Struct Biol 8:737-739, 2001. (Pubitemid 32803584)
16. Ibrahim HR, Matsuzaki T, and Aoki T. Genetic evidence that antibacterial activity of lysozyme is independent of its catalytic function. FEBS Lett 506:27-32, 2001. (Pubitemid 32925226)
17. Laible NJ, and Germaine GR. Bactericidal activity of human lysozyme, muramidase-inactive lysozyme, and cationic polypeptides against Streptococcus sanguis and Streptococcus faecalis: Inhibition by chitin oligosaccharides. Infect Immun 48:720-728, 1985. (Pubitemid 15021320)
18. Masschalck B, Deckers D, and Michiels CW. Lytic and nonlytic mechanism of inactivation of Gram-positive bacteria by lysozyme under atmospheric and high hydrostatic pressure. J Food Prot 65:1916-1923, 2002. (Pubitemid 36017023)
19. Woods CM, Hooper DN, Ooi EH, et al. Human lysozyme has fungicidal activity against nasal fungi. Am J Rhinol Allergy 25:236-240, 2011.
20. Woods CM, Lee VS, Hussey DJ, et al. Lysozyme expression is increased in the sinus mucosa of patients with chronic rhinosinusitis. Rhinology 50:147-156, 2012.
21. Collins MM, Nair SB, Der-Haroutian V, et al. Effect of using multiple culture media for the diagnosis of noninvasive fungal sinusitis. Am J Rhinol 19:41-45, 2005. (Pubitemid 40444003)
22. Kaliner MA. Human nasal host defense and sinusitis. J Allergy Clin Immunol 90:424-430, 1992.
23. Smith JJ, Travis SM, Greenberg EP, and Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229-236, 1996. (Pubitemid 26118164)
24. Singh PK, Tack BF, McCray PB Jr, and Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 279:L799-L805, 2000.
25. Travis SM, Conway BA, Zabner J, et al. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 20:872-879, 1999. (Pubitemid 129540846)
26. Tomee JF, Hiemstra PS, Heinzel-Wieland R, and Kauffman HF. Antileukoprotease: An endogenous protein in the innate mucosal defense against fungi. J Infect Dis 176:740-747, 1997. (Pubitemid 27360541)
27. Joris L, Dab I, and Quinton PM. Elemental composition of human airway surface fluid in healthy and diseased airways. Am Rev Respir Dis 148:1633-1637, 1993.
28. Govindaraju K, Cowley EA, Eidelman DH, and Lloyd DK. Microanalysis of lung airway surface fluid by capillary electrophoresis with conductivity detection. Anal Chem 69:2793-2797, 1997.
29. Knowles MR, Robinson JM, Wood RE, et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest 100:2588-2595, 1997. (Pubitemid 27514899)
30. Washington N, Steele RJ, Jackson SJ, et al. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm 198:139-146, 2000. (Pubitemid 30184851)
31. England RJ, Homer JJ, Knight LC, and Ell SR. Nasal pH measurement: A reliable and repeatable parameter. Clin Otolaryngol Allied Sci 24:67-68, 1999. (Pubitemid 29116483)
32. Fabricant ND. Significance of the pH of nasal secretions in situ. Arch Otolaryngol. 33:13, 1941.
33. Harvey RH, Hannan SA, Badia L, and Scadding G. Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Library 1:42, 2009.
34. Kassel JC, King D, and Spurling GK. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev 3:CD006821, 2010.
35. Brown CL, and Graham SM. Nasal irrigations: Good or bad? Curr Opin Otolaryngol Head Neck Surg 12:9-13, 2004. (Pubitemid 38130696)
36. Dorschner RA, Lopez-Garcia B, Peschel A, et al. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J 20:35-42, 2006. (Pubitemid 43100473)
37. Jeney EV, Raphael GD, Meredith SD, and Kaliner MA. Abnormal nasal glandular secretion in recurrent sinusitis. J Allergy Clin Immunol 86:10-18, 1990. (Pubitemid 20226838)
38. Raphael GD, Jeney EV, Baraniuk JN, et al. Pathophysiology of rhinitis. Lactoferrin and lysozyme in nasal secretions. J Clin Invest 84:1528-1535, 1989. (Pubitemid 19272241)
39. Kalfa VC, Spector SL, Ganz T, and Cole AM. Lysozyme levels in the nasal secretions of patients with perennial allergic rhinitis and recurrent sinusitis. Ann Allergy Asthma Immunol 93:288-292, 2004. (Pubitemid 39294735)